(Foto: Jyrki Siikanen)
Prof. Ann-Christine Syvänen
Ann-Christine.Syvanen@medsci.uu.se
Address:
Molecular Medicine
Department of Medical Sciences
Entrance 70, 3rd floor
Research dept. II
University Hospital
SE-751 85 UPPSALA
The research group in Molecular Medicine headed by Professor Ann-Christine Syvänen was started in 1998. The group studies human diseases using modern technology for genomics.
Professor Syvänen also heads the SNP&SEQ Technology Platform that offers genotyping and next generation sequencing services and training to academic researchers. The SNP&SEQ Technology Platform is part of the genomics platform of Science for Life Laboratory in Uppsala and is also funded by the Swedish Council for Research Infrastructures (VR-RFI).
We co-organize courses in molecular medicine and massively parallel sequencing targeted at students of different levels.
A good overview of our group can be read in a recent EU-publication
Use the tab-menu above to view information about our research, courses and services.
News |
|
2013-01-07 During Christmas the SNP&SEQ-platform installed a new HiSeq 2500-instrument. This instrument allows sequencing of 2 x 150 bp and decreases the run time from 11 days to 27 hours. Currently the SNP&SEQ-platform offers sequencing using four HiSeq- and one MiSeq-instrument. |
|
2012-12-02 15 new loci for coronary artery disease were published on-line in Nature Genetics on December 2nd. Both the molecular medicine group and the SNP&SEQ platform were involved in the study. |
|
Publication in Nature Genetics 2012-11-11 A new publication in Nature Genetics (Nov 11) presents identification of 14 new risk loci for rheumatoid arthritis (RA) by genotyping a custom designed Immunochip. For this study the SNP&SEQ-platform genotyped about 1000 samples from Umeå. There are now 46 known genetic risk loci for RA. |
|
2012-08-30 The SNP&SEQ Technology Platform has recently installed a third HiSeq2000 instrument and a second iScan instrument, including a new dual autoloader from Illumina. |
|
Two publications in Nature Genetics 2012-08-12 Nature Genetics has published two large-scale association studies where the SNP&SEQ-platform have been involved by genotyping sub-sets of the samples. |
|
2012-06-06 Former group member Johanna Sandling has recieved an international post doc grant from VR-MH. |
|
2012-04-23 Large grant for epigenetic and genomic analyses of the brain from VR, FAS, Formas and Vinnova to Molecular Medicine and the SNP&SEQ platform. |
|
2012-03-16 The SNP&SEQ Technology Platform has installed a MiSeq instrument from Illumina. |
|
The Swedish Childhood Cancer Foundation 2011-12-14 Molecular Medicine research group has received funding from the Swedish Childhood Cancer Foundation. |
|
2011-11-17 VR-RFI has granted 6.7 million SEK for running costs to the SNP&SEQ platform. |
|
2011-10-04 Molecular Medicine research group has received funding from the K&A Wallenberg foundation. |
|
2011-01-18 The Molecular Medicine group contributes to the ESGI infra-structure by technology development, eg. allele-specific gene expression and epigenetics. |
